Clinical trial · Interventional
The Jules Bordet Institute Molecular Profiling Program Feasibility Trial
THE JULES BORDET INSTITUTE PROGRAM FOR MOLECULAR PROFILING OF METASTATIC LESIONS: FEASIBILITY. PRECISION - Feasibility.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Prior to the use of genomic tests for patient inclusion in clinical trials, it is essential for the Jules Bordet Institute (JBI) to pilot the logistical and technical aspects by examining the feasibility and turnaround time of performing and obtaining data from a few key molecular assays. Patients with metastatic colorectal cancer, non-small cell lung cancer or melanoma will be enrolled. Biopsie from metastatic lesions will be performed. A targeted cancer gene screen assay will be performed using DNA sequencing. Results will be discussed during a molecular screening tumor board.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer Metastatic | — | UNRESOLVED | — |
| Metastatic Melanoma | Melanoma | CURATED_BROADER | 0.78 |
| Metastatic Non-Small Cell Lung Carcinoma | Lung Non-Small Cell Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Biopsy of a metastatic lesion. | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Sequencing of a metastatic lesion.
- description
- Biopsy of a metastatic lesion followed by a targeted cancer gene screen.
- interventionNames
- Procedure: Biopsy of a metastatic lesion.
Primary outcomes (3)
- measure
- Quality of the biopsies
- timeFrame
- 1 month
- description
- Percentage of frozen and FFPE core biopsies that are able to provide at least 1.5 μg of DNA of high quality suitable for molecular testing.
- measure
- Technical failure rate.
- timeFrame
- 1 month
- description
- Frequency of failures of each pathological and molecular tests.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Written informed consent for all study procedures according to local regulatory requirements prior to enrollment into the study. * Age ≥ 18 years. * Histologically proven metastatic or locally recurrent CRC, NSCLC or melanoma. * Tumor tissue (FFPE and frozen) from recurrent or metastatic lesions available for research purposes. Exclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) Performance Status \>2. * The biopsy procedure is estimated to be too risky for the patient. * Any anti-VEGF or anti-VEGFR treatment administered less than 3 weeks before new biopsy procedure. * No appropriate washout period for patients on anticoagulation therapy.
References
Publications (0)
Data not yet available